☰

Swathi Ramakrishnan, Ph.D. - Publications

Affiliations: 
2014 Roswell Park . Cancer Pathology and Prevention (Experimental) State University of New York, Buffalo, Buffalo, NY, United States 
Area:
Oncology
Tree Info Grants Similar researchers PubMed Report error

42 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Athans S, Krishnan N, Ramakrishnan S, Cortes Gomez E, Lage-Vickers S, Rak M, Kazmierczak Z, Ohm J, Attwood K, Wang J, Woloszynska A. STAG2 expression is associated with adverse survival outcomes and regulates cell phenotype in muscle-invasive bladder cancer. Cancer Research Communications. 2: 1129-1143. PMID 36275363 DOI: 10.1158/2767-9764.crc-22-0155  0.369
2021 Mastri M, Ramakrishnan S, Shah SD, Karasik E, Gillard BM, Moser MT, Farmer BK, Azabdaftari G, Chatta GS, Woloszynska A, Eng KH, Foster BA, Huss WJ. Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartment. American Journal of Clinical and Experimental Urology. 9: 416-434. PMID 34993263  0.334
2020 Krishnan N, Aquila L, Vickers SL, Ramakrishnan S, Atwood K, Hu Q, Cortes EG, Wang J, Woloszynska A. Abstract A22: STAG2, a novel genetic regulator of bladder cancer Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Bladder19-A22  0.43
2020 Ramakrishnan S, Peng X, Gomez EC, Attwood K, Yan L, Wilton J, Azabdaftari G, Mohler J, Wang J, Woloszynska A. Abstract B087: Role of GATA-4-Androgen-AR axis in prostate cancer from African American men Cancer Epidemiology, Biomarkers & Prevention. DOI: 10.1158/1538-7755.Disp19-B087  0.301
2019 Elbanna M, Orillion AR, Damayanti NP, Adelaiye-Ogala R, Shen L, Miles KM, Chintala S, Ciamporcero E, Ramakrishnan S, Ku SY, Rex K, Caenepeel S, Coxon A, Pili R. Dual inhibition of angiopoietin-TIE2 and MET alters the tumor microenvironment and prolongs survival in a metastatic model of renal cell carcinoma. Molecular Cancer Therapeutics. PMID 31582532 DOI: 10.1158/1535-7163.Mct-18-1202  0.593
2019 Bunch B, Krishnan N, Greenspan RD, Ramakrishnan S, Attwood K, Yan L, Qi Q, Wang D, Morrison C, Omilian A, Bshara W, Pili R, Trump DL, Johnson C, Woloszynska A. TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC). Cell Cycle (Georgetown, Tex.). 1-12. PMID 31318640 DOI: 10.1080/15384101.2019.1638693  0.584
2019 Ramakrishnan S, Granger V, Rak M, Hu Q, Attwood K, Aquila L, Krishnan N, Osiecki R, Azabdaftari G, Guru K, Chatta G, Gueron G, McNally L, Ohm J, Wang J, et al. Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. Cell Death and Differentiation. PMID 30692641 DOI: 10.1038/S41418-019-0278-9  0.458
2018 Ramakrishnan S, Peng X, Qi Q, Hu Q, Azabdaftari G, Pop E, Mohler J, Attwood K, Yan L, Wang J, Woloszynska-Read A. Abstract B72: DNA methylation and genetic alterations contribute to aggressive prostate cancer in African American men Cancer Epidemiology, Biomarkers & Prevention. 27. DOI: 10.1158/1538-7755.Disp17-B72  0.362
2017 Ramakrishnan S, Hu Q, Krishnan N, Wang D, Smit E, Granger V, Rak M, Attwood K, Johnson C, Morrison C, Pili R, Chatta G, Guru K, Gueron G, McNally L, et al. Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer. Cell Death & Disease. 8: 3217. PMID 29242529 DOI: 10.1038/S41419-017-0024-5  0.579
2016 Wei L, Chintala S, Ciamporcero E, Ramakrishnan S, Elbanna M, Wang J, Hu Q, Glenn ST, Murakami M, Liu L, Cortes Gomez E, Sun Y, Conroy J, Miles KM, Malathi K, et al. Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts. Oncotarget. PMID 27823983 DOI: 10.18632/Oncotarget.13062  0.533
2016 Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Attwood K, Chintala S, Shen L, Ellis L, Sotomayor P, Swetzig W, Huang R, Conroy D, Orillion A, Das G, Pili R. HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma. Bmc Cancer. 16: 617. PMID 27506904 DOI: 10.1186/S12885-016-2604-7  0.568
2016 Mori H, Yao Y, Learman BS, Kurozumi K, Ishida J, Ramakrishnan SK, Overmyer KA, Xue X, Cawthorn WP, Reid MA, Taylor M, Ning X, Shah YM, MacDougald OA. Induction of WNT11 by hypoxia and hypoxia-inducible factor-1α regulates cell proliferation, migration and invasion. Scientific Reports. 6: 21520. PMID 26861754 DOI: 10.1038/Srep21520  0.318
2015 Majumder K, Arora N, Modi S, Chugh R, Nomura A, Giri B, Dawra R, Ramakrishnan S, Banerjee S, Saluja A, Dudeja V. A Novel Immunocompetent Mouse Model of Pancreatic Cancer with Robust Stroma: a Valuable Tool for Preclinical Evaluation of New Therapies. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. PMID 26582596 DOI: 10.1007/s11605-015-2985-y  0.326
2015 Zhang H, Ramakrishnan SK, Triner D, Centofanti B, Maitra D, Győrffy B, Sebolt-Leopold JS, Dame MK, Varani J, Brenner DE, Fearon ER, Omary MB, Shah YM. Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1. Science Signaling. 8: ra98. PMID 26443705 DOI: 10.1126/Scisignal.Aac5418  0.374
2015 Ciamporcero E, Shen H, Ramakrishnan S, Yu Ku S, Chintala S, Shen L, Adelaiye R, Miles KM, Ullio C, Pizzimenti S, Daga M, Azabdaftari G, Attwood K, Johnson C, Zhang J, et al. YAP activation protects urothelial cell carcinoma from treatment-induced DNA damage. Oncogene. PMID 26119935 DOI: 10.1038/Onc.2015.219  0.627
2015 Kirk JS, Schaarschuch K, Dalimov Z, Lasorsa E, Ku S, Ramakrishnan S, Hu Q, Azabdaftari G, Wang J, Pili R, Ellis L. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer. Oncotarget. 6: 3136-46. PMID 25605014 DOI: 10.18632/Oncotarget.3077  0.637
2015 Adelaiye R, Ciamporcero E, Miles KM, Sotomayor P, Bard J, Tsompana M, Conroy D, Shen L, Ramakrishnan S, Ku SY, Orillion A, Prey J, Fetterly G, Buck M, Chintala S, et al. Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Molecular Cancer Therapeutics. 14: 513-22. PMID 25519701 DOI: 10.1158/1535-7163.Mct-14-0208  0.59
2015 Ciamporcero E, Miles KM, Adelaiye R, Ramakrishnan S, Shen L, Ku S, Pizzimenti S, Sennino B, Barrera G, Pili R. Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Molecular Cancer Therapeutics. 14: 101-10. PMID 25381264 DOI: 10.1158/1535-7163.Mct-14-0094  0.607
2015 Shen L, Sundstedt A, Ciesielski M, Miles KM, Celander M, Adelaiye R, Orillion A, Ciamporcero E, Ramakrishnan S, Ellis L, Fenstermaker R, Abrams SI, Eriksson H, Leanderson T, Olsson A, et al. Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunology Research. 3: 136-48. PMID 25370534 DOI: 10.1158/2326-6066.Cir-14-0036  0.65
2015 Luo W, Ma Y, Baldino C, Caserta J, Ramakrishnan S, Roberto P, Johnson C, Trump D. Abstract 5056: PIM-1 kinase regulates vitamin D receptor signaling in human renal carcinoma cells Cancer Research. 75: 5056-5056. DOI: 10.1158/1538-7445.Am2015-5056  0.376
2015 Orillion A, Adelaiye-Ogala R, Shen L, Ciamporcero E, Ku SY, Ramakrishnan S, Elbanna M, Chintala S, Pili R. Abstract 4110: Inhibition of angiopoietin 1/2 and c-MET impairs metastatic potential in a patient derived xenograft of renal carcinoma Cancer Research. 75: 4110-4110. DOI: 10.1158/1538-7445.Am2015-4110  0.576
2015 Ku S, Ramakrishnan S, Ciamporcero E, Xu B, Azabdaftari G, Cheney R, Pili R. Abstract 2546: HDAC and Hsp90 inhibition as therapeutic strategy for translocation renal cell carcinoma Cancer Research. 75: 2546-2546. DOI: 10.1158/1538-7445.Am2015-2546  0.663
2015 Shen L, Orillion A, Adelaiye R, Ciamporcero E, Ramakrishnan S, Pili R. Abstract 2514: Activity of a novel Foxp3-tumor cell vaccine in a murine model of renal cell carcinoma Cancer Research. 75: 2514-2514. DOI: 10.1158/1538-7445.Am2015-2514  0.59
2015 Elbanna MF, Ciamporcero E, Ramakrishnan S, Adelaiye R, Shen L, Orillion A, Ku S, Chintala S, Pili R. Abstract 1462: Characterization of patient-derived bladder cancer xenografts: role of xCT in response to cisplatin Cancer Research. 75: 1462-1462. DOI: 10.1158/1538-7445.Am2015-1462  0.574
2014 Ku S, Lasorsa E, Adelaiye R, Ramakrishnan S, Ellis L, Pili R. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer. Plos One. 9: e103680. PMID 25072314 DOI: 10.1371/Journal.Pone.0103680  0.623
2014 Buck MJ, Raaijmakers LM, Ramakrishnan S, Wang D, Valiyaparambil S, Liu S, Nowak NJ, Pili R. Alterations in chromatin accessibility and DNA methylation in clear cell renal cell carcinoma. Oncogene. 33: 4961-5. PMID 24186201 DOI: 10.1038/Onc.2013.455  0.596
2014 Chintala S, Nguyen H, Ramakrishnan S, Ku S, Ciamporcero E, Miles KM, Pili R. Abstract 686: Regulation of intracellular sequestration of sunitinib by cystine transporter xCT in renal cancer Cancer Research. 74: 686-686. DOI: 10.1158/1538-7445.Am2014-686  0.614
2014 Ramakrishnan S, Ku S, Swetzig W, Conroy D, Shen L, Chintala S, Sotomayor P, Miles KM, Adelaiye R, Ciamporcero E, Orillion A, Ellis L, Das G, Pili R. Abstract 4061: Evidence for hdac6 and er-α association in a subset of clear cell renal cell carcinoma Cancer Research. 74: 4061-4061. DOI: 10.1158/1538-7445.Am2014-4061  0.61
2014 Ciamporcero ES, Shen H, Chintala S, Ramakrishnan S, Ku SY, Miles KM, Pizzimenti S, Johnson C, Zhang J, Barrera G, Pili R. Abstract 3754: Hippo pathway effector Yes-associated protein and cisplatin resistance in transitional cell carcinoma of the bladder Cancer Research. 74: 3754-3754. DOI: 10.1158/1538-7445.Am2014-3754  0.634
2014 Adelaiye R, Miles KM, Ciamporcero E, Conroy D, Ramakrishnan S, Orillion A, Ku SY, Elbanna M, shen L, Chintala S, Pili R. Abstract 1375: Epigenetic changes associated with resistance to sunitinib in human clear cell renal cell carcinoma models Cancer Research. 74: 1375-1375. DOI: 10.1158/1538-7445.Am2014-1375  0.658
2014 Orillion A, Miles KM, Shen L, Adelaiye R, Ciamporcero E, Ramakrishnan S, Ku SY, Elbanna M, Chintala S, Pili R. Abstract 1013: Angiopoietin 1/2 inhibition impairs tumor growth in an orthotopic model of renal cell carcinoma Cancer Research. 74: 1013-1013. DOI: 10.1158/1538-7445.Am2014-1013  0.645
2013 Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a Pten defecient model of prostate cancer. Oncotarget. 4: 2225-36. PMID 24163230 DOI: 10.18632/Oncotarget.1314  0.61
2013 Ramakrishnan S, Ellis L, Pili R. Histone modifications: implications in renal cell carcinoma. Epigenomics. 5: 453-62. PMID 23895657 DOI: 10.2217/Epi.13.40  0.575
2013 Ramakrishnan S, Pili R. Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma. Cancer Journal (Sudbury, Mass.). 19: 333-40. PMID 23867515 DOI: 10.1097/Ppo.0B013E3182A09E07  0.596
2013 Ramakrishnan S, Sotomayor P, Ellis L, Chintala S, Pili R. Abstract 2987: VHL dependent and independent regulation of HDAC expression and activity in renal cell carcinomas. Cancer Research. 73: 2987-2987. DOI: 10.1158/1538-7445.Am2013-2987  0.661
2012 Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, Shrikant P, Fenstermaker R, Pili R. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. Plos One. 7: e30815. PMID 22303460 DOI: 10.1371/Journal.Pone.0030815  0.634
2012 Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Pili R. Development of a castrate resistant transplant tumor model of prostate cancer. The Prostate. 72: 587-91. PMID 21796655 DOI: 10.1002/Pros.21465  0.609
2012 Ellis L, Ramakrishnan S, Ku S, Pili R. Abstract C7: Targeting the androgen receptor with novel combination therapeutic strategies in metastatic/castrate-resistant prostate cancer Cancer Research. 72: C7-C7. DOI: 10.1158/1538-7445.Prca2012-C7  0.601
2012 Ramakrishnan S, Sotomayor P, Lehet K, Pili R. Abstract 5016: Epigenetics in renal cell carcinoma Cancer Research. 72: 5016-5016. DOI: 10.1158/1538-7445.Am2012-5016  0.649
2012 Ramakrishnan S, Pili R. Epigenetic targeting and histone deacetylase inhibition in RCC Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Targets. 2147483647: 193-211. DOI: 10.1007/978-1-4614-2400-0_9  0.583
2011 Ellis L, Lehet K, Ramakrishnan S, Adelaiye R, Miles KM, Wang D, Liu S, Atadja P, Carducci MA, Pili R. Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression. Plos One. 6: e27178. PMID 22087262 DOI: 10.1371/Journal.Pone.0027178  0.652
2011 Ellis L, Lehet K, Ramakrishnan S, Miles K, Wang D, Liu S, Atadja P, Carducci M, Pili R. 7054 POSTER Concurrent Histone Deacetylase and Mammalian Target of Rapamycin Inhibition Attenuate Androgen Receptor and Hypoxia Signaling Associated With Alterations in MicroRNA Expression European Journal of Cancer. 47: S501. DOI: 10.1016/S0959-8049(11)72005-6  0.478
Show low-probability matches.